Instructions for Bifidumbacterin probiotic 5 doses
English product name
Bifidumbacterin
Release Form
caps. 50 million KOE (5 doses): 10, 20, 30, 30, 40 or 50 pcs
Description:
Capsules 1 cap.
Bifidobacterium longum 50 million SOME
ATX codes
A07FA Biological antidiarrhoeal preparations regulating the balance of intestinal microflora
Clinical-pharmacological groups / Group affiliation
Preparation for regulating the balance of intestinal microflora (probiotic)
Active substance
Bifidobacterium longum
Pharmacotherapy group:
MIBP-eubiotic
Testimony Bifidumbacterin:
- Treatment and prevention of dysbacteriosis of different etiology in children and adults.
- Prolonged intestinal dysfunctions of unspecified etiology;
- acute intestinal infections (in the complex treatment of acute dysentery, salmonellosis, escherichiosis,
- viral diarrhea),
- long-term intestinal dysfunctions of staphylococcal etiology,
- and reconvestion treatment Acute intestinal infections with continued intestinal dysfunction;
- In the comprehensive treatment of children (including newborns, prematurely),
- patients with pneumonia,
- sepsis and other pyo-infectious diseases,
- to prevent or buy from them disorders of the intestinal function and prevent the development of ulcer-necrotic enterocolitis it;
- children with pre-orbit condition:
- born prematurely or with early signs of prematurity, receiving antibiotics in the early neonatal period;
- Children whose mothers had severe toxicoses,
- extragenital diseases had a long period of water-deprivation or other pathology;
- children of mothers who have lactose,
- nipple cracks,
- and who resume breast feeding after recovery from mastitis;
- weakened children with anemia,
- hypotrophy,
- rickets,
- diathesis and other allergies;
- In case of whooping cough,
- especially if they have any intestinal disorders;
- Early transfer of infants to artificial feeding; acute and chronic inflammatory diseases of the colon and small intestine (colitis, enterocolites) in older children and adults,
- taking place against the background of microflora disorders with deficiency or absence of bifidoflora;
- Intestinal dysfunction as a result of intestinal dysbacteriosis,
- which is a result of long-term antibacterial,
- hormonal,
- radiotherapy and other therapy,
- under stress situations and extreme conditions,
- as well as for the prevention of dysbacteriosis.
Method of use, course and dosage Bifidumbacterin:
For internal and local use.
The dose and treatment regimen are set individually, depending on the age, indications and dosage form used.
Use in liver disorders
The drug Bifidobacteria is allowed for use in the case of liver dysfunction
Application in elderly patients
Use is permitted in elderly patients.
Child use
In children (including premature infants), it is possible to use from the first days of life in medicinal forms intended for this category of patients according to age.
- Nosology (ICD codes)
- A02
- Other salmonella infections
- A03
- Shigellosis
- A04.8
- Other refined bacterial intestinal infections
- A05.0
- Staphylococcal food poisoning
- A08.4
- Viral intestinal infection unspecified
- A09.0
- Other and unspecified gastroenteritis and colitis of infectious origin
- K52.9
- Non-infectious gastroenteritis and colitis unspecified
- K63.8
- Other refined bowel diseases
- N76
- Other inflammatory diseases of the vagina and vulva
- N77.1
- Vaginitis, vulvite and vulvovaginitis for infectious and parasitic diseases classified in other headings
- N89.8
- Other non-inflammatory vaginal diseases
- N95.2
- Postmenopausal atrophic vaginitis
- O91
- Breast infections related to childbirth
- O92.0
- Injected nipple
- O92.1
- Nipple fracture related to childbirth
- P23
- Congenital pneumonia
- P36
- Bacterial sepsis of the newborn
- P92.9
- The problem of feeding a newborn is not specified
- Y40
- Systemic Antibiotics
- Y42
- Hormones and their synthetic substitutes and antagonists not classified in other rubrics
- Y84.2
- Radiological procedure and radiotherapy
- Z29.8
- Other specific preventive measures
- Z51.4
- Preparatory procedures for follow-up treatment or examination not classified elsewhere
Pharmacological effect Bifidumbacterin:
Live bifidobacteria have a high antagonistic activity against a wide range of pathogenic and opportunistic intestinal microorganisms (including staphylococci, proteus, enteropathogenic E. coli, shigella, some yeast-like fungi), restore the balance of intestinal and vaginal microflora, normalize intestinal digestive and protective functions, activate metabolic processes, increase non-specific resistance of the organism.
